MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives $35.00 Consensus Target Price from Analysts

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have been assigned a consensus rating of “Hold” from the five research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $35.00.

A number of analysts recently weighed in on INKT shares. Zacks Research raised shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 19th.

MiNK Therapeutics Stock Performance

Shares of NASDAQ:INKT opened at $12.71 on Tuesday. MiNK Therapeutics has a 1 year low of $4.56 and a 1 year high of $76.00. The stock has a market capitalization of $59.60 million, a P/E ratio of -4.19 and a beta of 0.34. The stock has a 50-day simple moving average of $11.76 and a 200-day simple moving average of $14.47.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.21. Analysts predict that MiNK Therapeutics will post -2.75 earnings per share for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.